drugset / Trial / NCT07499440
Safety and Efficacy of HB-1 for Post-Traumatic Stress Disorder
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo in male and female adult patients aged 18 to 65 years, inclusive, with Post-Traumatic Stress Disorder (PTSD).
Timeline
- Start
- 2026-06
- Primary completion
- 2027-09
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telmisartan | Other / unclassified | 64 mg | Oral |
| Subject | Telmisartan | Other / unclassified | 86 mg | Oral |
| Subject | Verapamil | Other / unclassified | 192 mg | Oral |
| Subject | Verapamil | Other / unclassified | 258 mg | Oral |